Autologous Cell Therapy-United States Market Status and Trend Report 2013-2023
Report Summary
Autologous Cell Therapy-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023
Main market players of Autologous Cell Therapy in United States, with company and product introduction, position in the Autologous Cell Therapy market
Market status and development trend of Autologous Cell Therapy by types and applications
Cost and profit status of Autologous Cell Therapy, and marketing status
Market growth drivers and challenges
The report segments the United States Autologous Cell Therapy market as:
United States Autologous Cell Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Autologous Cell Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bone Marrow
Epidermis
United States Autologous Cell Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others
United States Autologous Cell Therapy Market: Players Segment Analysis (Company and Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and Gross Margin):
BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Autologous Cell Therapy-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023
Main market players of Autologous Cell Therapy in United States, with company and product introduction, position in the Autologous Cell Therapy market
Market status and development trend of Autologous Cell Therapy by types and applications
Cost and profit status of Autologous Cell Therapy, and marketing status
Market growth drivers and challenges
The report segments the United States Autologous Cell Therapy market as:
United States Autologous Cell Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Autologous Cell Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bone Marrow
Epidermis
United States Autologous Cell Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others
United States Autologous Cell Therapy Market: Players Segment Analysis (Company and Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and Gross Margin):
BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF AUTOLOGOUS CELL THERAPY
1.1 Definition of Autologous Cell Therapy in This Report
1.2 Commercial Types of Autologous Cell Therapy
1.2.1 Bone Marrow
1.2.2 Epidermis
1.3 Downstream Application of Autologous Cell Therapy
1.3.1 Neurology
1.3.2 Orthopedics
1.3.3 Cancer
1.3.4 Wound Healing
1.3.5 CVD
1.3.6 Autoimmune
1.3.7 Others
1.4 Development History of Autologous Cell Therapy
1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
1.5.1 United States Autologous Cell Therapy Market Status and Trend 2013-2023
1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Autologous Cell Therapy in United States 2013-2017
2.2 Consumption Market of Autologous Cell Therapy in United States by Regions
2.2.1 Consumption Volume of Autologous Cell Therapy in United States by Regions
2.2.2 Revenue of Autologous Cell Therapy in United States by Regions
2.3 Market Analysis of Autologous Cell Therapy in United States by Regions
2.3.1 Market Analysis of Autologous Cell Therapy in New England 2013-2017
2.3.2 Market Analysis of Autologous Cell Therapy in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Autologous Cell Therapy in The Midwest 2013-2017
2.3.4 Market Analysis of Autologous Cell Therapy in The West 2013-2017
2.3.5 Market Analysis of Autologous Cell Therapy in The South 2013-2017
2.3.6 Market Analysis of Autologous Cell Therapy in Southwest 2013-2017
2.4 Market Development Forecast of Autologous Cell Therapy in United States 2018-2023
2.4.1 Market Development Forecast of Autologous Cell Therapy in United States 2018-2023
2.4.2 Market Development Forecast of Autologous Cell Therapy by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Autologous Cell Therapy in United States by Types
3.1.2 Revenue of Autologous Cell Therapy in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Autologous Cell Therapy in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Autologous Cell Therapy in United States by Downstream Industry
4.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Autologous Cell Therapy by Downstream Industry in New England
4.2.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Autologous Cell Therapy by Downstream Industry in The Midwest
4.2.4 Demand Volume of Autologous Cell Therapy by Downstream Industry in The West
4.2.5 Demand Volume of Autologous Cell Therapy by Downstream Industry in The South
4.2.6 Demand Volume of Autologous Cell Therapy by Downstream Industry in Southwest
4.3 Market Forecast of Autologous Cell Therapy in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY
5.1 United States Economy Situation and Trend Overview
5.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Autologous Cell Therapy in United States by Major Players
6.2 Revenue of Autologous Cell Therapy in United States by Major Players
6.3 Basic Information of Autologous Cell Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Players
6.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 BioTime, Inc.
7.1.1 Company profile
7.1.2 Representative Autologous Cell Therapy Product
7.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.
7.2 BrainStorm Cell Therapeutics
7.2.1 Company profile
7.2.2 Representative Autologous Cell Therapy Product
7.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics
7.3 Caladrius Biosciences, Inc.
7.3.1 Company profile
7.3.2 Representative Autologous Cell Therapy Product
7.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.
7.4 Fibrocell Science, Inc.
7.4.1 Company profile
7.4.2 Representative Autologous Cell Therapy Product
7.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.
7.5 Opexa Therapeutics, Inc.
7.5.1 Company profile
7.5.2 Representative Autologous Cell Therapy Product
7.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.
7.6 Pharmicell Co., Inc.
7.6.1 Company profile
7.6.2 Representative Autologous Cell Therapy Product
7.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.
7.7 Regeneus Ltd.
7.7.1 Company profile
7.7.2 Representative Autologous Cell Therapy Product
7.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.
7.8 TiGenix NV
7.8.1 Company profile
7.8.2 Representative Autologous Cell Therapy Product
7.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV
7.9 TxCell SA
7.9.1 Company profile
7.9.2 Representative Autologous Cell Therapy Product
7.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA
7.10 U.S. Stem Cell, Inc.
7.10.1 Company profile
7.10.2 Representative Autologous Cell Therapy Product
7.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.
7.11 Vericel Corporation
7.11.1 Company profile
7.11.2 Representative Autologous Cell Therapy Product
7.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY
8.1 Industry Chain of Autologous Cell Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY
9.1 Cost Structure Analysis of Autologous Cell Therapy
9.2 Raw Materials Cost Analysis of Autologous Cell Therapy
9.3 Labor Cost Analysis of Autologous Cell Therapy
9.4 Manufacturing Expenses Analysis of Autologous Cell Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF AUTOLOGOUS CELL THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Autologous Cell Therapy in This Report
1.2 Commercial Types of Autologous Cell Therapy
1.2.1 Bone Marrow
1.2.2 Epidermis
1.3 Downstream Application of Autologous Cell Therapy
1.3.1 Neurology
1.3.2 Orthopedics
1.3.3 Cancer
1.3.4 Wound Healing
1.3.5 CVD
1.3.6 Autoimmune
1.3.7 Others
1.4 Development History of Autologous Cell Therapy
1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
1.5.1 United States Autologous Cell Therapy Market Status and Trend 2013-2023
1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Autologous Cell Therapy in United States 2013-2017
2.2 Consumption Market of Autologous Cell Therapy in United States by Regions
2.2.1 Consumption Volume of Autologous Cell Therapy in United States by Regions
2.2.2 Revenue of Autologous Cell Therapy in United States by Regions
2.3 Market Analysis of Autologous Cell Therapy in United States by Regions
2.3.1 Market Analysis of Autologous Cell Therapy in New England 2013-2017
2.3.2 Market Analysis of Autologous Cell Therapy in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Autologous Cell Therapy in The Midwest 2013-2017
2.3.4 Market Analysis of Autologous Cell Therapy in The West 2013-2017
2.3.5 Market Analysis of Autologous Cell Therapy in The South 2013-2017
2.3.6 Market Analysis of Autologous Cell Therapy in Southwest 2013-2017
2.4 Market Development Forecast of Autologous Cell Therapy in United States 2018-2023
2.4.1 Market Development Forecast of Autologous Cell Therapy in United States 2018-2023
2.4.2 Market Development Forecast of Autologous Cell Therapy by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Autologous Cell Therapy in United States by Types
3.1.2 Revenue of Autologous Cell Therapy in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Autologous Cell Therapy in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Autologous Cell Therapy in United States by Downstream Industry
4.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Autologous Cell Therapy by Downstream Industry in New England
4.2.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Autologous Cell Therapy by Downstream Industry in The Midwest
4.2.4 Demand Volume of Autologous Cell Therapy by Downstream Industry in The West
4.2.5 Demand Volume of Autologous Cell Therapy by Downstream Industry in The South
4.2.6 Demand Volume of Autologous Cell Therapy by Downstream Industry in Southwest
4.3 Market Forecast of Autologous Cell Therapy in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY
5.1 United States Economy Situation and Trend Overview
5.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Autologous Cell Therapy in United States by Major Players
6.2 Revenue of Autologous Cell Therapy in United States by Major Players
6.3 Basic Information of Autologous Cell Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Players
6.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 BioTime, Inc.
7.1.1 Company profile
7.1.2 Representative Autologous Cell Therapy Product
7.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.
7.2 BrainStorm Cell Therapeutics
7.2.1 Company profile
7.2.2 Representative Autologous Cell Therapy Product
7.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics
7.3 Caladrius Biosciences, Inc.
7.3.1 Company profile
7.3.2 Representative Autologous Cell Therapy Product
7.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.
7.4 Fibrocell Science, Inc.
7.4.1 Company profile
7.4.2 Representative Autologous Cell Therapy Product
7.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.
7.5 Opexa Therapeutics, Inc.
7.5.1 Company profile
7.5.2 Representative Autologous Cell Therapy Product
7.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.
7.6 Pharmicell Co., Inc.
7.6.1 Company profile
7.6.2 Representative Autologous Cell Therapy Product
7.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.
7.7 Regeneus Ltd.
7.7.1 Company profile
7.7.2 Representative Autologous Cell Therapy Product
7.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.
7.8 TiGenix NV
7.8.1 Company profile
7.8.2 Representative Autologous Cell Therapy Product
7.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV
7.9 TxCell SA
7.9.1 Company profile
7.9.2 Representative Autologous Cell Therapy Product
7.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA
7.10 U.S. Stem Cell, Inc.
7.10.1 Company profile
7.10.2 Representative Autologous Cell Therapy Product
7.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.
7.11 Vericel Corporation
7.11.1 Company profile
7.11.2 Representative Autologous Cell Therapy Product
7.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY
8.1 Industry Chain of Autologous Cell Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY
9.1 Cost Structure Analysis of Autologous Cell Therapy
9.2 Raw Materials Cost Analysis of Autologous Cell Therapy
9.3 Labor Cost Analysis of Autologous Cell Therapy
9.4 Manufacturing Expenses Analysis of Autologous Cell Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF AUTOLOGOUS CELL THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
